PDX Model Market Size & Analysis Report by Type, By Tumor type, By Application, By End-user and By Region – Global Opportunities & Forecast 2021-2028
PDX Model Market Size & Analysis Report by Type (Mice Models and Rat Models), By Tumor type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Hematological Tumor Models and Others), By Application (Preclinical Drug Development, Biomarker Analysis and Basic Cancer Research), By End-user (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic & Research Institutions) and By Region
Published Date: Jul - 2021 | Report Format: Excel/PPT | Report Code: UP2115-001001
PDX model market is anticipated to grow at a CAGR of 16.1% during forecast period and estimated to reach USD 403 million by 2028.
Introduction of the PDX Model Market Report
The patient-derived xenografts (PDX) models are an effective tool in the biomedical research field in which the cancerous tumor or cells from the patients are transferred or implanted into immunodeficient rodents like mice or rats. They are developed for cancer research based on expectations that these models have the capability to retain the tumor characteristics, particularly for the patient-derived orthotropic xenograft. Basically, these models include the uninterrupted transfer of human disease samples into mice.
To have an edge over the competition by knowing the market dynamics and current trends of “PDX Model Market”, request for Sample Report here
Market Dynamic
Key Drivers and Emerging Trends
The rising demand for personalized medicine is a key factor driving the global PDX model market growth. It is the process of developing customized medications to provide individualized treatment and care based on personal and genetic variations. They are prepared using animal models, in which immunodeficient models are transplanted with human tissues, and the disease expressed is noted. It is followed by treating the model with drugs/gene therapies to find the apt treatment, this way aiding to bring out appropriate medicines. The development of therapies for deadly diseases such as cancer has attracted noteworthy attention. Currently, cancer is a major load on healthcare facilities across the globe. According to GLOBOCAN, in 2020, it is estimated that 19.3 million cases and 10 million cancer deaths were registered. The In vitro and In vivo approaches are being evolved to fight the increasing incidences of cancer and helps in carrying out proper treatments to patients. A significant evolution in this regard is the arrival of PDX models, as they have high power to predict the effectiveness of standard and novel anti-cancer treatments. Due to this advantage, these models are increasingly being used in preclinical studies.
Restraint in the PDX Model Market
However, considering the cost of creating and maintaining these models and requirement of expensive drugs used in it are the factors hindering the growth of the market. PDX experiments can cost thousands of dollars, even in the case of a single patient. Moreover, using PDX models in government-funded basic research can also be cost-prohibitive. These are the major factors restraining the PDX models market size.
Do you want to know more about the Research process and detailed Methodology, Request Research Methodology of this report
Tumor type – Segment Analysis
Based on the tumor type, Respiratory Tumor Models segment is expected to grow at a higher CAGR during the forecast period in PDX models market share. This is attributed to the growing research-based activities in oncology as well as the increasing need to generate PDX models based on lung cancer due to rising cancer cases. For instance, in 2021, researchers of the Chinese Academy of Sciences (CAS) and their collaborators discovered the novel mechanism controlling TH9-mediated cancer immunotherapy and explained the underlying molecular mechanism. According to the World Health Organization (WHO), cancer is the second most leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Many companies are aiming to develop advanced products for the treatment of chronic disease in order to maintain their competitive advantage and penetrate new regional markets. Moreover, the increase in funding for companies involved in cancer research is another key factor influencing the global PDX models market.
Application – Segment Analysis
Based on the application, basic cancer research is projected to dominate the PDX models market share during the forecast period owing to an increase in the adoption of PDX models for basic cancer research. Basic cancer research is the description of cancer biology and exploring mechanisms that are involved prognosis or understanding of cancer. PDX models essentially provide important in-vivo and ex-vivo evidence to aid basic studies of cancer, including tumor characterization, tumorigenesis, and metastasis. Moreover, the increasing number of clinical trials is another vital factor driving this segment growth.
In case, any of your pain points areas are not covered in the current scope of this report, Request for Free Customization here
Regional – Segment Analysis:
Based on the region, North America segment is expected to grow at a higher CAGR during the forecast period owing to a rise in funding initiatives and creating awareness among patients regarding personalized medicine. Patient-derived tumor xenografts are recognized as very relevant preclinical cancer models. According to American Cancer Society estimates, in 2018, there were 1,735,350 new cases of cancer detected in the US. Also, in 2018, the National Institute of Cancer expanded the storage of cancer research models to store more of such models. Hence, these are the key factors driving the PDX models market in North America.
Top Market Players
Various notable players operating in the market include JSR Corporation., WuXi AppTec, THE JACKSON LABORATORY, Charles River Laboratories., Oncodesign, Envigo, Pharmatest Services, Hera Biolabs., EPO Berlin-Buch GmbH, Xentech, among others.
Key Developments:
-
- In 2019, Charles River Laboratories., updated its online Tumor Model Compendium by adding 79 new patient-derived xenografts, ten new cell line-derived xenografts, and 36 new cell line models for several cancer types, including anal, colon, lung, and renal cancer, as well as leukemia and melanoma.
- In 2019, Envigo acquired the assets of the research models business unit of Horizon Discovery Group plc.
Segments covered in the Report:
The global PDX Model market has been segmented on the basis of Type, Tumor type, Application, End-user and regions. Based on Type, the market is segmented into Mice Models and Rat Models. Based on Tumor type, the market is segmented into Gastrointestinal Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Hematological Tumor Models and Others. Based on Application, the market is segmented into Preclinical Drug Development, Biomarker Analysis and Basic Cancer Research. Based on End-user the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic & Research Institutions.
For detailed scope of the “PDX Model Market” report request a Sample Copy of the report
Key questions answered in this research report:
-
- At what pace is global PDX Model market growing? What will be the growth trend in the future?
- What are the key drivers and restraints in PDX Model market? What will be the impact of drivers and restraints in the future?
- What are the regional revenues and forecast breakdowns? Which are the major regional revenue pockets for growth in the global PDX Model market?
- Which Type generated maximum revenues in 2019 and identify the most promising Type during the forecast period?
- What are the various Tumor type areas of global PDX Model market and how they are poised to grow?
- What companies are the major participants in this market and their business strategies, how does the competitive landscape look like?
Report Coverage |
Details |
Market Base Year |
2020 |
Market Forecast Period |
2021-2028 |
Market Revenues (2028) |
USD 403 million |
Base Year & Forecast Units |
Revenues (USD Million) |
Market Segment | By Type, By Tumor type, By Application, By End-user, By Region |
Regional Coverage | Asia Pacific, Europe, North America, and RoW |
Companies Profiled | JSR Corporation., WuXi AppTec, THE JACKSON LABORATORY, Charles River Laboratories., Oncodesign, Envigo, Pharmatest Services, Hera Biolabs., EPO Berlin-Buch GmbH, Xentech, among others; a total of 10 companies covered. |
25% Free Customization Available | We will customize this report up to 25% as a free customization to address our client’s specific requirements |
Market Segmentation
Global PDX Model Market by Type
-
- Mice Models
- Rat Models
Global PDX Model Market by Tumor type
-
- Gastrointestinal Tumor Models
- Gynecological Tumor Models
- Respiratory Tumor Models
- Urological Tumor Models
- Hematological Tumor Models
- Others
Global PDX Model Market by Application
-
- Preclinical Drug Development
- Biomarker Analysis
- Basic Cancer Research
Global PDX Model Market by End-user
-
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutions
Global PDX Model Market by Region
-
- North America PDX Model Market (Option 1: As a part of the free 25% customization)
- North America PDX Model Market by Type
- North America PDX Model Market by Tumor type
- North America PDX Model Market by Application
- North America PDX Model Market by End-user
- US PDX Model Market All-Up
- Canada PDX Model Market All-Up
- Europe PDX Model Market (Option 2: As a part of the free 25% customization)
- Europe PDX Model Market by Type
- Europe PDX Model Market by Tumor type
- Europe PDX Model Market by Application
- Europe PDX Model Market by End-user
- UK PDX Model Market All-Up
- Germany PDX Model Market All-Up
- France PDX Model Market All-Up
- Spain PDX Model Market All-Up
- Rest of Europe PDX Model Market All-Up
- Asia-Pacific PDX Model Market (Option 3: As a part of the free 25% customization)
- Asia-Pacific PDX Model Market by Type
- Asia-Pacific PDX Model Market by Tumor type
- Asia-Pacific PDX Model Market by Application
- Asia-Pacific PDX Model Market by End-user
- China PDX Model Market All-Up
- India PDX Model Market All-Up
- Japan PDX Model Market All-Up
- Rest of APAC PDX Model Market All-Up
- RoW PDX Model Market (Option 4: As a part of the free 25% customization)
- RoW PDX Model Market by Type
- RoW PDX Model Market by Tumor type
- RoW PDX Model Market by Application
- RoW PDX Model Market by End-user
- Brazil PDX Model Market All-Up
- South Africa PDX Model Market All-Up
- Saudi Arabia PDX Model Market All-Up
- UAE PDX Model Market All-Up
- Rest of world (remaining countries of the LAMEA region) PDX Model Market All-Up
- North America PDX Model Market (Option 1: As a part of the free 25% customization)
Major Players Operating in the PDX Model (Option 5: As a part of the Free 25% Customization – Profiles of 5 Additional Companies of your Choice)
-
- JSR Corporation.
- WuXi AppTec
- THE JACKSON LABORATORY
- Charles River Laboratories.
- Oncodesign
- Envigo
- Pharmatest Services
- Hera Biolabs.
- EPO Berlin-Buch GmbH
- Xentech
Frequently Asked Question About This Report
PDX model market [UP2115-001001]
The leading players in this market are JSR Corporation., WuXi AppTec, THE JACKSON LABORATORY, Charles River Laboratories., Oncodesign, Envigo, Pharmatest Services, Hera Biolabs., EPO Berlin-Buch GmbH, Xentech, among others.
The growth rate of PDX Model Market during 2021-2028 is 16.1%.
The Respiratory Tumor Models segment is projected to grow at a higher CAGR during the forecast period in PDX models market share. This is attributed to the growing research-based activities in oncology as well as the increasing need to generate PDX models based on lung cancer due to rising cancer cases.
The basic cancer research is expected to dominate the PDX models market share during the forecast period owing to an increase in the adoption of PDX models for basic cancer research.
Licensing Options
Single-User License:
The report is used by the purchaser (One Individual) only
Multi-User License:Report is shared with maximum 5 users (employees) including the purchaser of the purchasing corporation only
Corporate License:
Report is shared with unlimited user (employees) of the purchasing corporation only
The report is used by the purchaser (One Individual) only
Multi-User License:Report is shared with maximum 5 users (employees) including the purchaser of the purchasing corporation only
Corporate License:
Report is shared with unlimited user (employees) of the purchasing corporation only
PDX Model Market Size & Analysis Report by Type, By Tumor type, By Application, By End-user and By Region – Global Opportunities & Forecast 2021-2028
$ 4,499.00 – $ 6,649.00